Focused On-demand Library for Eukaryotic translation initiation factor 5A-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P63241

UPID:

IF5A1_HUMAN

Alternative names:

Eukaryotic initiation factor 5A isoform 1; Rev-binding factor; eIF-4D

Alternative UPACC:

P63241; A8K9A0; D3DTP2; P10159; Q16182; Q7L7L3; Q7Z4L1; Q9D0G2

Background:

Eukaryotic translation initiation factor 5A-1, also known as eIF-4D, plays a pivotal role in cellular processes including translation elongation and termination, ribosome stalling rescue, actin dynamics, and cell cycle progression. It is essential for the translation of polyproline-containing peptides and other motifs that stall the ribosome. Additionally, it acts as a ribosome quality control cofactor and is involved in mRNA decay, stress response, and cell wall integrity maintenance.

Therapeutic significance:

The association of eIF-4D with Faundes-Banka syndrome, a disorder marked by developmental delay and dysmorphic features, underscores its therapeutic significance. Understanding the role of eIF-4D could open doors to potential therapeutic strategies for treating this syndrome and possibly other related conditions.